These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27238065)

  • 21. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
    Blader JC; Schooler NR; Jensen PS; Pliszka SR; Kafantaris V
    Am J Psychiatry; 2009 Dec; 166(12):1392-401. PubMed ID: 19884222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 2: antipsychotics and traditional mood stabilizers.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):52-61. PubMed ID: 25886656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
    Blader JC; Pliszka SR; Jensen PS; Schooler NR; Kafantaris V
    Pediatrics; 2010 Oct; 126(4):e796-806. PubMed ID: 20837589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.
    Armenteros JL; Lewis JE; Davalos M
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of severe child aggression (TOSCA) study: Design challenges.
    Farmer CA; Arnold LE; Bukstein OG; Findling RL; Gadow KD; Li X; Butter EM; Aman MG
    Child Adolesc Psychiatry Ment Health; 2011 Nov; 5(1):36. PubMed ID: 22074813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder.
    Gorman DA; Gardner DM; Murphy AL; Feldman M; Bélanger SA; Steele MM; Boylan K; Cochrane-Brink K; Goldade R; Soper PR; Ustina J; Pringsheim T
    Can J Psychiatry; 2015 Feb; 60(2):62-76. PubMed ID: 25886657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder.
    Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
    Kronenberger WG; Giauque AL; Lafata DE; Bohnstedt BN; Maxey LE; Dunn DW
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):334-47. PubMed ID: 17630867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
    Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL;
    Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
    LeBlanc JC; Binder CE; Armenteros JL; Aman MG; Wang JS; Hew H; Kusumakar V
    Int Clin Psychopharmacol; 2005 Sep; 20(5):275-83. PubMed ID: 16096518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parent-Reported Improvements in Family Functioning in a Randomized Controlled Trial of Lisdexamfetamine for Treatment of Parental Attention-Deficit/Hyperactivity Disorder.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphery H; Pelham WE
    J Child Adolesc Psychopharmacol; 2017 Apr; 27(3):250-257. PubMed ID: 27991835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylphenidate in children with oppositional defiant disorder and both comorbid chronic multiple tic disorder and ADHD.
    Gadow KD; Nolan EE; Sverd J; Sprafkin J; Schneider J
    J Child Neurol; 2008 Sep; 23(9):981-90. PubMed ID: 18474932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ.
    Aman M; Buitelaar J; Smedt GD; Wapenaar R; Binder C
    J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):220-32. PubMed ID: 15910206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-morbid disruptive behavior disorder and aggression predict functional outcomes and differential response to risperidone versus divalproex in pharmacotherapy for pediatric bipolar disorder.
    West AE; Weinstein SM; Celio CI; Henry D; Pavuluri MN
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):545-53. PubMed ID: 22136096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TOSCA: no longer just an opera.
    Jensen PS
    J Am Acad Child Adolesc Psychiatry; 2014 Sep; 53(9):938-41. PubMed ID: 25151415
    [No Abstract]   [Full Text] [Related]  

  • 38. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
    van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.